Percheron Therapeutics LimitedASX: PER

Dosing completed in ATL1102 Phase II DMD trial

Nov 20, 2019 at 3:41 AM UTC · Issued by Percheron Therapeutics Limited

Percheron Therapeutics Limited has released a press release.

View Attachment